Halofuginone, another molecule identified via high-throughput screening, suppresses Nrf2 accumulation by repressing protein synthesis via prolyl-tRNA synthetase inhibition and ultimately sensitizing an ESCC cell line harboring mutant Nrf2 to chemotherapy [214]. This evidence concerns the gene NFE2L2 and esophageal squamous cell carcinoma.